These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38290657)

  • 1. Polo-like kinase 4 promotes tumorigenesis and glucose metabolism in glioma by activating AKT1 signaling.
    Wang B; Zhang X; Li ZS; Wei C; Yu RZ; Du XZ; He YJ; Ren Y; Zhen YW; Han L
    Cancer Lett; 2024 Mar; 585():216665. PubMed ID: 38290657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway.
    Wang J; Ren D; Sun Y; Xu C; Wang C; Cheng R; Wang L; Jia G; Ren J; Ma J; Tu Y; Ji H
    J Cell Mol Med; 2020 Apr; 24(7):3931-3947. PubMed ID: 32126150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase.
    Ding Z; Liang J; Li J; Lu Y; Ariyaratna V; Lu Z; Davies MA; Westwick JK; Mills GB
    PLoS One; 2010 Mar; 5(3):e9910. PubMed ID: 20361045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma.
    Kanwore K; Kanwore K; Adzika GK; Abiola AA; Guo X; Kambey PA; Xia Y; Gao D
    Front Immunol; 2022; 13():831636. PubMed ID: 35392088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Assessment of Preanalytic Variables on Clinical Evaluation of PI3/AKT/mTOR Signaling Activity in Diffuse Glioma.
    Beccari S; Mohamed E; Voong V; Hilz S; Lafontaine M; Shai A; Lim Y; Martinez J; Switzman B; Yu RL; Lupo JM; Chang EF; Hervey-Jumper SL; Berger MS; Costello JF; Phillips JJ
    Mod Pathol; 2024 Jun; 37(6):100488. PubMed ID: 38588881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RRAGB-mediated suppression of PI3K/AKT exerts anti-cancer role in glioblastoma.
    Li Q; Liu X; Mao J; Liu S; Hou B; Li K; Fang D
    Biochem Biophys Res Commun; 2023 Oct; 676():149-157. PubMed ID: 37517217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study.
    Zhong S; Zhang Z; Guo Z; Yang W; Dou G; Lv X; Wang X; Ge J; Wu B; Pan X; Wang H; Mou Y
    Bioengineered; 2022 May; 13(5):12003-12020. PubMed ID: 35603567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fraxetin down-regulates polo-like kinase 4 (PLK4) to inhibit proliferation, migration and invasion of prostate cancer cells through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway.
    Ma Z; Sun Y; Peng W
    Bioengineered; 2022 Apr; 13(4):9345-9356. PubMed ID: 35387563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
    Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
    Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
    J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo‑like kinase 4 promotes tumorigenesis and induces resistance to radiotherapy in glioblastoma.
    Wang J; Zuo J; Wang M; Ma X; Gao K; Bai X; Wang N; Xie W; Liu H
    Oncol Rep; 2019 Apr; 41(4):2159-2167. PubMed ID: 30816483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RPA3 promotes the proliferation, migration, and invasion of gliomas by activating the PI3K-AKT-mTOR pathway.
    Liang L; Zhao Z; Jin Q; Zhang S; Zhao Z; Li X
    Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):80-86. PubMed ID: 37571896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of Akt at the C-terminal tail triggers Akt activation.
    Liu P; Wang Z; Wei W
    Cell Cycle; 2014; 13(14):2162-4. PubMed ID: 24933731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer effects of veratramine via the phosphatidylinositol-3-kinase/serine-threonine kinase/mechanistic target of rapamycin and its downstream signaling pathways in human glioblastoma cell lines.
    Kim D; Kwon W; Park S; Kim W; Park JK; Han JE; Cho GJ; Yun S; Han SH; Kim MO; Ryoo ZY; Choi SK
    Life Sci; 2022 Jan; 288():120170. PubMed ID: 34826438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypomethylated PDZK1 acts as a tumorigenic gene in glioma by interacting with AKT1.
    Ren X; Deng D; Xiang S; Feng J
    Aging (Albany NY); 2024 Apr; 16(8):7174-7187. PubMed ID: 38669103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.